May 6th 2024
Editor-in-chief Tina Tan, MD, FAAP, FIDSA, FPIDS, highlights the April 2024 issue of Contemporary Pediatrics.
Clinical Consultations™: Managing Depressive Episodes in Patients with Bipolar Disorder Type II
View More
Medical Crossfire®: Understanding the Advances in Bipolar Disease Treatment—A Comprehensive Look at Treatment Selection Strategies
View More
'REEL’ Time Patient Counseling: The Diagnostic and Treatment Journey for Patients With Bipolar Disorder Type II – From Primary to Specialty Care
View More
Clinical ShowCase™: Finding the Best Path Forward for Patients with COPD
View More
A Tethered Approach to Type 2 Diabetes Care – Connecting Insulin Regimens with Digital Technology
View More
Surv.AI Says™: What Clinicians and Patients Are Saying About Glucose Management in the Technology Age
View More
Masters of pediatric dermatology course offered to healthcare providers
July 25th 2023The fully online training program, the MOPD Foundations of Pediatric Dermatology Certificate Course, was created by the founders of the Masters of Pediatric Dermatology (MOPD) Symposium and includes lectures, presentations, and downloadable resources for clinicians.
Friction-induced blistering on a child’s feet
July 14th 2023You are called to the hospital nursery to evaluate a healthy full-term newborn boy who developed painful flaccid blisters and erosions on the tops of his feet and ankles shortly after birth. His mother had a history of similar recurrent skin lesions that healed with scarring. She also had oral and gastrointestinal tract involvement. What's the diagnosis?
Higher risk of autoimmune, other disorders associated with children of mothers with alopecia areata
May 26th 2023New data indicates that increased risk for offspring in developing different disorders is associated with maternal alopecia areata exposure, expanding the available information on alopecia and maternal autoimmunity.
Tapinarof cream 1% demonstrates positive topline results for treating pediatric AD
May 16th 2023The once-daily topical cream for the treatment of atopic dermatitis (AD) has demonstrated positive topline results in 2 phase 3 studies in adults and children aged 2 years and up. According to Dermavant, a supplemental new drug application (sNDA) filed with the FDA is anticipated in Q1 of 2024.
FDA accepts NDA for roflumilast foam 0.3% for seborrheic dermatitis in 9 years and up
April 18th 2023Roflumilast is a once-daily, topical phosphodiesterase type 4 (PDE4) inhibitor under development for treatment of inflammatory dermatoses, focusing on the hair-bearing areas including the face, scalp, and trunk.
Establishing accurate case definitions for childhood respiratory and skin conditions
February 17th 2023A research letter addresses the challenges of accurately diagnosing asthma, atopic eczema, and allergic rhinitis in children under 5 years old and the use of Read codes and prescription data as diagnostic criteria.